Drug Profile
Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies
Alternative Names: TTP 018Latest Information Update: 23 Sep 2014
Price :
$50
*
At a glance
- Originator SIGA Technologies; TransTech Pharma
- Class Small molecules; Viral vaccines
- Mechanism of Action Peptide hydrolase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Orthopoxvirus infections
Most Recent Events
- 21 Sep 2010 No development reported - Preclinical for Orthopoxvirus infections in USA (unspecified route)
- 25 Jul 2007 TTP 018 is in preclinical development
- 31 May 2004 This programme is still in active development - 17th International Conference on Antiviral Research (ICAR-2004)